Table 2 Screening of gatifloxacin and its synthesized derivatives using whole blood for their immune modulating inhibitory properties
Compound | CPM Reading | Inhibition% | IC50 ± SD | ||||
|---|---|---|---|---|---|---|---|
Conc (μg/mL) | 50 | 12.5 | 3.12 | 50 | 12.5 | 3.12 | |
4 | 18538.3 | 25229.4 | 29076.6 | 45.86 | 26.32 | 15.09 | >50 |
5 | 476.3 | 33339.6 | 33370.4 | 97.6 | −70.7 | −70.9 | 24 ± 0.5 |
6 | 10678.5 | 22012.4 | 30970.5 | 45.3 | −12.7 | −58.6 | 23.9 ± 9 |
7 | 286.6 | 4554.4 | 18804.47 | 99.16 | 86.7 | 45.09 | 3.7 ± 0.1 |
8 | 6988.7 | 46099.7 | 40114.8 | 64.2 | −136 | −105.4 | 35.5 ± 0.4 |
9 | 16087.9 | 40831.9 | 40689 | 17.6 | −109.1 | −108.3 | 43.5 |
10 | 40893.6 | 46979.2 | 45283.2 | −109.4 | −140.5 | −131.8 | >50 |
11 | 13122.8 | 33977.4 | 35965.9 | 32.8 | −74 | −84.1 | 37.5 ±1.5 |
12 | 13691.3 | 41857.5 | 39169.8 | 30 | −114.3 | −100.5 | 40.7 ± 0.5 |
13 | 42380 | 70222.1 | 52258.6 | −23.7 | −105.05 | −52.59 | >50 |
14 | 257.3 | 2182.5 | 10766.9 | 98.7 | 88.8 | 44.9 | <3.12 |
15 | 7470.6 | 29308.1 | 32117.4 | 61.8 | −50.1 | −64.4 | 27 ± 2.6 |
16 | 34845.8 | 43188.6 | 38111.9 | −78.4 | −121.1 | −95.1 | >50 |
17 | 10892.5 | 31624.6 | 35370.22 | 44.2 | −61.9 | −81.1 | 33.0 ± 0.8 |
18 | 27012.8 | 30291.9 | 30529.1 | −38.3 | −55.1 | −56.3 | >50 |
19 | 117 | 14599.9 | 22362.3 | 99.4 | 25.2 | −14.5 | 6.8 ± 0.3 |
20 | 2932.7 | 14825.1 | 22921.5 | 85 | 24 | −17.4 | 8.8 ± 2.8 |
Gatifloxacin | 24450.9 | 38657.7 | 33427.3 | −25.2 | −97.9 | −71.1 | > 50 |
Standard | 654.2 | 1906.8 | 1945.7 | 98.089 | 94.432 | 94.318 | < 3.12 |